Aclaris Therapeutics, Inc. (ACRS) Stock Grade

About Aclaris Therapeutics, Inc.'s fundamentals

Aclaris Therapeutics is a biotechnology company with a market capitalization of $369.2 million that reported significant financial challenges in its latest fiscal year. The company experienced a steep 58.2% year-over-year decline in revenue and posted a net loss, reflected in a negative net margin of -829.6%, indicating the company is spending substantially more than it generates in revenue. The company does not currently pay a dividend and lacks meaningful profitability metrics (P/E ratio and return on equity are not applicable given the net loss position).